Neoadjuvant Treatment for a cT4cN+ HER2+ Breast Cancer: Case Report of a Therapeutic Success

Anticancer Res. 2024 Jun;44(6):2755-2758. doi: 10.21873/anticanres.17084.

Abstract

Background: HER2 positive disease accounts for 15-20% of early breast cancer. Achieving a pathological complete response after neoadjuvant chemotherapy (NACT) improves prognosis and decreases risk of recurrence.

Case report: Our case report aimed to highlight an emblematic clinical success and benefit of NACT with the addition of pertuzumab to the standard trastuzumab/taxane/anthracycline combination in a patient with a 9 cm breast neoplasm and extensive lymph node involvement (>4 pathological lymph nodes).

Conclusion: Achieving a complete pathological response with NACT, should be the main goal, especially in patients with triple negative and HER2 positive breast cancer.

Keywords: Breast cancer; HER2+; neoadjuvant.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
  • Breast Neoplasms* / drug therapy
  • Breast Neoplasms* / metabolism
  • Breast Neoplasms* / pathology
  • Female
  • Humans
  • Middle Aged
  • Neoadjuvant Therapy* / methods
  • Receptor, ErbB-2* / metabolism
  • Taxoids / administration & dosage
  • Taxoids / therapeutic use
  • Trastuzumab / therapeutic use
  • Treatment Outcome

Substances

  • Receptor, ErbB-2
  • ERBB2 protein, human
  • pertuzumab
  • Trastuzumab
  • Antibodies, Monoclonal, Humanized
  • Taxoids